1197953-47-1 Usage
General Description
2-(DiMethylphosphoryl)aniline is a chemical compound with the molecular formula C8H12NO2P. It is a pale yellow to brown liquid with a faint amine odor. 2-(diMethylphosphoryl)aniline is commonly used as an intermediate in the synthesis of pharmaceuticals and organic pigments. It is also utilized as an inhibitor and stabilizer in industrial processes. 2-(DiMethylphosphoryl)aniline is highly flammable and should be handled with caution, as it can cause irritation to the skin, eyes, and respiratory system. It is important to follow proper safety procedures when working with this chemical.
Check Digit Verification of cas no
The CAS Registry Mumber 1197953-47-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,9,7,9,5 and 3 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1197953-47:
(9*1)+(8*1)+(7*9)+(6*7)+(5*9)+(4*5)+(3*3)+(2*4)+(1*7)=211
211 % 10 = 1
So 1197953-47-1 is a valid CAS Registry Number.
1197953-47-1Relevant articles and documents
DIMETHYLPHOSPHINE OXIDE COMPOUND
-
Paragraph 0048, (2021/02/25)
Disclosed is an application of a series of dimethylphosphine oxide compounds in the preparation of an LRRK2 kinase activity inhibitor-related drug, specifically an application of the compound shown in formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an LRRK2 kinase activity inhibitor-related drug.
Polymorphism of novel spiroarylphosphine oxide
-
Paragraph 0114; 0118-0120, (2019/11/20)
The invention relates to a polymorphic substance of a compound (2-((5-chloro-2-((2-methoxyl-4-(9-methyl-3,9-diaza-sprio[5.5]hendecane-3-yl)phenyl)amino)pyrimidine-4-yl)amino)phenyl)dimethyl phosphineoxide (compound I). The invention further relates to a m
TYK2 INHIBITORS AND USES THEREOF
-
Paragraph 001166; 001167, (2018/05/15)
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
